German funds select Imraldi due to price
Executive Summary
Deep initial discounts of up to 40% versus AbbVie’s Humira (adalimumab) original have won Biogen’s Imraldi alternative a nationwide supply contract with Germany’s GWQ group of health insurance funds.
You may also be interested in...
Kabi Introduces Idacio Into Crowded German Adalimumab Market
Fresenius Kabi is entering a German adalimumab market in which Amgen, Mylan and Sandoz are already competing against AbbVie’s Humira reference brand. In this environment, Fresenius’ sales expectations are modest.
Biogen Claims Lead Among Adalimumab Biosimilars In Europe
With quarterly sales up to $36m, Biogen says its Imraldi rival to Humira is the market-leading adalimumab biosimilar in Europe.
AdvaMed Offers Plan To Strengthen Medtech Supply Chain
Medtech trade group AdvaMed is offering a list of recommendations to beef up the nation’s medical technology supply chain. Public-private partnerships are central to the group’s plan.